Literature DB >> 1696607

Comparative therapeutic efficacy of recombinant interferons-alpha, -beta, and -gamma against alphatogavirus, bunyavirus, flavivirus, and herpesvirus infections.

A J Pinto1, P S Morahan, M Brinton, D Stewart, E Gavin.   

Abstract

Recombinant (r) preparations of interferons (IFN)-alpha, -beta, and -gamma were shown to protect mice against experimental virus infections with herpes simplex virus type 2 (HSV-2), and with three RNA-containing viruses from different families: Banzi, a flavivirus; Semliki Forest virus (SFV), an alphatogavirus; and Caraparu, a bunyavirus. The antiviral effects of the three different types of IFN were different with each virus. HSV-2 was the most sensitive virus, followed by SFV. Against Banzi virus, IFN-gamma was only effective when given both before and after infection. Against Caraparu virus, only IFN-gamma had a significant effect. These results suggest that IFN therapy might be valuable in human infections with these viruses, but that the correct choice of IFN and dose regimen is likely to be important.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1696607     DOI: 10.1089/jir.1990.10.293

Source DB:  PubMed          Journal:  J Interferon Res        ISSN: 0197-8357


  15 in total

1.  Interplay between alpha/beta and gamma interferons with B, T, and natural killer cells in the defense against herpes simplex virus type 1.

Authors:  Sabine Vollstedt; Susi Arnold; Cornelia Schwerdel; Marco Franchini; Gottfried Alber; James P Di Santo; Mathias Ackermann; Mark Suter
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

2.  Correlation between breakdown of the blood-brain barrier and disease outcome of viral encephalitis in mice.

Authors:  Aaron L Olsen; John D Morrey; Donald F Smee; Robert W Sidwell
Journal:  Antiviral Res       Date:  2006-12-20       Impact factor: 5.970

3.  Prophylactic treatment with recombinant Eimeria protein, alone or in combination with an agonist cocktail, protects mice from Banzi virus infection.

Authors:  Justin G Julander; John W Judge; Aaron L Olsen; Barnett Rosenberg; Kristiina Schafer; Robert W Sidwell
Journal:  Antiviral Res       Date:  2006-12-04       Impact factor: 5.970

4.  Modulation of Dengue virus infection in human cells by alpha, beta, and gamma interferons.

Authors:  M S Diamond; T G Roberts; D Edgil; B Lu; J Ernst; E Harris
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

5.  Antiviral activity of limitin against encephalomyocarditis virus, herpes simplex virus, and mouse hepatitis virus: diverse requirements by limitin and alpha interferon for interferon regulatory factor 1.

Authors:  Shin-Ichiro Kawamoto; Kenji Oritani; Hideo Asada; Isao Takahashi; Jun Ishikawa; Hitoshi Yoshida; Masahide Yamada; Naoko Ishida; Hidetoshi Ujiie; Hiroaki Masaie; Yoshiaki Tomiyama; Yuji Matsuzawa
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

6.  Interferons, interferon inducers, and interferon-ribavirin in treatment of flavivirus-induced encephalitis in mice.

Authors:  Pieter Leyssen; Christian Drosten; Marcus Paning; Nathalie Charlier; Jan Paeshuyse; Erik De Clercq; Johan Neyts
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

7.  Activation and evasion of innate antiviral immunity by herpes simplex virus.

Authors:  Jesper Melchjorsen; Sampsa Matikainen; Søren R Paludan
Journal:  Viruses       Date:  2009-11-05       Impact factor: 5.048

8.  A Novel Agonist of the TRIF Pathway Induces a Cellular State Refractory to Replication of Zika, Chikungunya, and Dengue Viruses.

Authors:  Kara M Pryke; Jinu Abraham; Tina M Sali; Bryan J Gall; Iris Archer; Andrew Liu; Shelly Bambina; Jason Baird; Michael Gough; Marita Chakhtoura; Elias K Haddad; Ilsa T Kirby; Aaron Nilsen; Daniel N Streblow; Alec J Hirsch; Jessica L Smith; Victor R DeFilippis
Journal:  mBio       Date:  2017-05-02       Impact factor: 7.867

Review 9.  Cytokine determinants of viral tropism.

Authors:  Grant McFadden; Mohamed R Mohamed; Masmudur M Rahman; Eric Bartee
Journal:  Nat Rev Immunol       Date:  2009-08-21       Impact factor: 53.106

10.  Characterization of a Novel Human-Specific STING Agonist that Elicits Antiviral Activity Against Emerging Alphaviruses.

Authors:  Tina M Sali; Kara M Pryke; Jinu Abraham; Andrew Liu; Iris Archer; Rebecca Broeckel; Julia A Staverosky; Jessica L Smith; Ahmed Al-Shammari; Lisi Amsler; Kayla Sheridan; Aaron Nilsen; Daniel N Streblow; Victor R DeFilippis
Journal:  PLoS Pathog       Date:  2015-12-08       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.